SCHOLAR ROCK HOLDING CORPORATION Revenue
SCHOLAR ROCK HOLDING CORPORATION (SRRK) reported Revenue of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-06
- SCHOLAR ROCK HOLDING CORPORATION revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $0.00.
- SCHOLAR ROCK HOLDING CORPORATION revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $0.00.
- SCHOLAR ROCK HOLDING CORPORATION revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $0.00.
- SCHOLAR ROCK HOLDING CORPORATION revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $0.00.
- SCHOLAR ROCK HOLDING CORPORATION revenue from contract with customer, excluding assessed tax for fiscal 2025 was $0.00.
- SCHOLAR ROCK HOLDING CORPORATION revenue from contract with customer, excluding assessed tax for fiscal 2022 was $33.19M, a 76.41% increase from fiscal 2021.
- SCHOLAR ROCK HOLDING CORPORATION revenue from contract with customer, excluding assessed tax for fiscal 2021 was $18.82M, a 22.16% increase from fiscal 2020.
- SCHOLAR ROCK HOLDING CORPORATION revenue from contract with customer, excluding assessed tax for fiscal 2020 was $15.40M, a 24.83% decline from fiscal 2019.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 | $0.00 derived: sum of 3 quarters · filed 2026-08-06 | $0.00 derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-07 | $0.00 derived: sum of 2 quarters · filed 2026-05-07 | $0.00 derived: sum of 3 quarters · filed 2026-05-07 | |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $0.00 derived: sum of 2 quarters · filed 2026-03-03 | $0.00 10-K · filed 2026-03-03 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $0.00 10-Q · filed 2025-11-14 | ||
| 2025-06-30 | $0.00 10-Q · filed 2025-08-06 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $0.00 derived: sum of 2 quarters · filed 2024-03-19 | $0.00 derived: sum of 3 quarters · filed 2024-03-19 | $33.19M 10-K · filed 2024-03-19 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $0.00 derived: sum of 2 quarters · filed 2023-11-07 | $33.19M 10-Q · filed 2023-11-07 | $37.24M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $33.19M 10-Q · filed 2023-08-09 | $37.24M derived: sum of 3 quarters · filed 2023-08-09 | $42.71M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $33.19M 10-Q · filed 2023-05-09 | $37.24M derived: sum of 2 quarters · filed 2023-05-09 | $42.71M derived: sum of 3 quarters · filed 2023-05-09 | $47.30M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $4.05M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $9.51M derived: sum of 2 quarters · filed 2023-03-07 | $14.11M derived: sum of 3 quarters · filed 2023-03-07 | $18.82M 10-K · filed 2023-03-07 |
| 2021-09-30 | $5.46M 10-Q · filed 2022-11-14 | $10.06M derived: sum of 2 quarters · filed 2022-11-14 | $14.77M 10-Q · filed 2022-11-14 | $18.20M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $4.59M 10-Q · filed 2022-08-08 | $9.30M 10-Q · filed 2022-08-08 | $12.74M derived: sum of 3 quarters · filed 2022-08-08 | $15.78M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $4.71M 10-Q · filed 2022-05-16 | $8.14M derived: sum of 2 quarters · filed 2022-05-16 | $11.18M derived: sum of 3 quarters · filed 2022-05-16 | $15.08M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $3.44M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-07 | $6.47M derived: sum of 2 quarters · filed 2022-03-07 | $10.37M derived: sum of 3 quarters · filed 2022-03-07 | $15.40M 10-K · filed 2022-03-07 |
| 2020-09-30 | $3.04M 10-Q · filed 2021-11-09 | $6.94M derived: sum of 2 quarters · filed 2021-11-09 | $11.97M 10-Q · filed 2021-11-09 | $19.54M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | $3.90M 10-Q · filed 2021-08-10 | $8.93M 10-Q · filed 2021-08-10 | $16.50M derived: sum of 3 quarters · filed 2021-08-10 | $21.28M derived: sum of 4 quarters · filed 2021-08-10 |
| 2020-03-31 | $5.03M 10-Q · filed 2021-05-13 | $12.60M derived: sum of 2 quarters · filed 2021-05-13 | $17.38M derived: sum of 3 quarters · filed 2021-05-13 | $22.42M derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | $7.57M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | $12.35M derived: sum of 2 quarters · filed 2021-03-09 | $17.39M derived: sum of 3 quarters · filed 2021-03-09 | $20.49M 10-K · filed 2021-03-09 |
| 2019-09-30 | $4.77M 10-Q · filed 2020-11-09 | $9.81M derived: sum of 2 quarters · filed 2020-11-09 | $12.92M 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $5.04M 10-Q · filed 2020-08-07 | $8.14M 10-Q · filed 2020-08-07 | ||
| 2019-03-31 | $3.11M 10-Q · filed 2020-05-07 | |||
| 2018-09-30 | $0.00 10-Q · filed 2018-11-08 | $0.00 derived: sum of 2 quarters · filed 2018-11-08 | $0.00 10-Q · filed 2018-11-08 | |
| 2018-06-30 | $0.00 10-Q · filed 2018-08-08 | $0.00 10-Q · filed 2018-08-08 | ||
| 2017-09-30 | $0.00 10-Q · filed 2018-11-08 | $0.00 derived: sum of 2 quarters · filed 2018-11-08 | $0.00 10-Q · filed 2018-11-08 | |
| 2017-06-30 | $0.00 10-Q · filed 2018-08-08 | $0.00 10-Q · filed 2018-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |